BRD1 and ovarian cancer: Overall, the mutational signature of C. elegans BRC-1 BRD-1 deficiency agrees with the flat profile of increased base substitutions described in HR deficient human cancers [23, 24], BRCA1 negative human lymphoblastic MA lines [25] and also resembles the pattern of SVs associated with BRCA1 loss in breast and ovarian cancers [26–28].